Literature DB >> 15292293

Detection of thyrotropin-receptor messenger ribonucleic acid (mRNA) and thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease: sensitive and specific markers for thyroid cancer.

Priya Chinnappa1, Leslie Taguba, Rosemarie Arciaga, Charles Faiman, Allan Siperstein, Adi E Mehta, Sethu K Reddy, Christian Nasr, Manjula K Gupta.   

Abstract

Because thyroid cancer cells express functional TSH receptors (TSHR), TSHR-mRNA in peripheral blood might serve as a tissue-/cancer-specific marker. We measured circulating TSHR-mRNA by RT-PCR in 51 normal controls, 27 patients with benign thyroid disease, 67 patients with treated differentiated thyroid cancer (DTC), and eight patients with newly diagnosed DTC, preoperatively. Results were compared with thyroglobulin (Tg) mRNA and serum Tg levels. TSHR-mRNA signals were not detected in normal controls and in 24 of 27 (89%) patients with benign thyroid disease. All 19 patients with treated DTC with evidence of distant or local disease tested positive for TSHR-mRNA (sensitivity 100%). Among patients with no evidence of disease, TSHR-mRNA was detected in 1 in 48 (specificity 98%). Six of the eight newly diagnosed DTC patients tested preoperatively were positive for TSHR-mRNA. The concordance between TSHR-mRNA and Tg-mRNA and between TSHR-mRNA and serum Tg was 95%. Fourteen patients with DTC (21%) had Tg antibodies, three with local disease (all positive for TSHR-mRNA), and 11 with no evidence of disease (all negative for TSHR-mRNA). Our results indicate that TSHR-mRNA and/or Tg-mRNA in peripheral blood are both equally sensitive and specific markers for monitoring thyroid cancer patients. Their principal value resides in the Tg antibody-positive patients in whom a positive or a negative mRNA value might have indicated or obviated the need for a whole-body scan. Furthermore, the high specificity combined with their ability to predict thyroid cancer preoperatively suggests a potential role in detecting thyroid cancer in patients with thyroid nodules.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15292293     DOI: 10.1210/jc.2003-031967

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  Current concepts and future directions in differentiated thyroid cancer.

Authors:  Donald S A McLeod
Journal:  Clin Biochem Rev       Date:  2010-02

2.  Circulating nucleic acids: An analysis of their occurrence in malignancies.

Authors:  Shankar Suraj; Chirag Dhar; Sweta Srivastava
Journal:  Biomed Rep       Date:  2016-11-16

3.  Peripheral blood mononuclear cells - Can they provide a clue to the pathogenesis of Graves' Orbitopathy?

Authors:  Madhurima Basak; Tamalika Sanyal; Anish Kar; Pritha Bhattacharjee; Madhusudan Das; Subhankar Chowdhury
Journal:  Endocrine       Date:  2021-09-20       Impact factor: 3.633

4.  Peripheral blood levels of thyroglobulin mRNA and serum thyroglobulin concentrations after radioiodine ablation of multinodular goiter with or without pre-treatment with recombinant human thyrotropin.

Authors:  I G S Rubio; M N C Silva; M Knobel; R Romão; R Possato; E M M S Gebrin; C Buchpiguel; G Medeiros-Neto
Journal:  J Endocrinol Invest       Date:  2007 Jul-Aug       Impact factor: 4.256

5.  Oncofoetal fibronectin--a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma.

Authors:  E Hesse; P B Musholt; E Potter; T Petrich; M Wehmeier; R von Wasielewski; R Lichtinghagen; T J Musholt
Journal:  Br J Cancer       Date:  2005-09-05       Impact factor: 7.640

Review 6.  Circulating tumor cells in thyroid carcinoma - the prognostic role of this biomarker. Review of the literature.

Authors:  Iulian Claudiu Bădulescu; Elena Bărbuş; Doina Piciu
Journal:  Clujul Med       Date:  2017-07-15

7.  Circulating thyrotropin receptor messenger ribonucleic acid is not an effective marker in the follow-up of differentiated thyroid carcinoma.

Authors:  Surasawadee Ausavarat; Jiraporn Sriprapaporn; Busara Satayaban; Wanna Thongnoppakhun; Aunchalee Laipiriyakun; Boontham Amornkitticharoen; Rujaporn Chanachai; Chaveevan Pattanachak
Journal:  Thyroid Res       Date:  2015-08-04

8.  Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology.

Authors:  José A González-Masiá; Damián García-Olmo; Dolores C García-Olmo
Journal:  Onco Targets Ther       Date:  2013-07-08       Impact factor: 4.147

9.  The evolution of biomarkers in thyroid cancer-from mass screening to a personalized biosignature.

Authors:  Raymon H Grogan; Elliot J Mitmaker; Orlo H Clark
Journal:  Cancers (Basel)       Date:  2010-05-20       Impact factor: 6.639

Review 10.  Thyroid malignant neoplasm-associated biomarkers as targets for oncolytic virotherapy.

Authors:  Mingxu Guan; Yanping Ma; Sahil Rajesh Shah; Gaetano Romano
Journal:  Oncolytic Virother       Date:  2016-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.